Advertising disclosure: we may earn a commission when you buy through links on this site. How we make money

HomeTrials › NCT07223983

Obesity & weight · Phase 1 · Recruiting now

Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)

NCT07223983 · Sponsor: Yale University

What this trial means for you

This study is recruiting now at 1 US site. It's studying Semaglutide 1.0 mg for alcohol use disorder, weight loss, bariatric surgery patients.

Who can joinAll sexes, 18 Years and older
Healthy volunteersNo — diagnosis required
What you'd takeSemaglutide 1.0 mg
Study length~8 months overall
Planned participants10
TypeInterventional (you receive treatment)

What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.

The study, in the sponsor's words

The purpose of this research study is to evaluate the feasibility of treating Alcohol Use Disorder with Semaglutide after metabolic and bariatric surgery in adults with overweight or obesity.

Can you join? The exact criteria

Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.

Full eligibility criteria (for you and your doctor)

Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study (up to 6 months: 3-month treatment plus 3-month follow up) * Age 18 and older * Have a BMI ≥30 (or BMI ≥27 with a medical comorbidity) and BMI ≤50 kg/m2 * Have had laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy within the past seven years * Meet current DSM-5 criteria for Alcohol Use Disorder * Be an otherwise healthy subject without uncontrolled medical problems, as determined by the study physician and medical co-investigators * Read, comprehend, and write English at a sufficient level to complete study-related materials * For females of reproductive potential: use of highly effective contraception and agreement to use such a method during study participation Exclusion Criteria: * Any of the following: myocardial infarction, stroke, hospitalization for unstable angina, or transient ischemic attack within the past 60 days prior to screening * History or presence of chronic or recurrent pancreatitis * History of malignant neoplasms within the past 5 years prior to screening * Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 * Is currently using other medications for weight loss or other GLP-1 receptor agonists * Has a history of allergy or sensitivity to Semaglutide * Has a co-existing psychiatric condition that requires hospitalization or more intensive treatment (such as bipolar mood disorders, psychotic illnesses, or severe depression) * Has untreated hypertension with a seated systolic blood pressure \> 160 mmHg, diastolic blood pressure \> 100 mmHg, or heart rate \> 100 beats/minute * Has current uncontrolled hypertension * Has current uncontrolled Type I or Type II diabetes mellitus * Has untreated hypothyroidism with a TSH \> 1.5 times the upper limit of normal for the test laboratory with repeat value that also exceeds this limit * Has active gallbladder disease * Has a history of severe renal, hepatic, neurological, chronic pulmonary disease, or any other unstable medical disorder * Has a recent history of substance use disorder (with the exception of cannabis or tobacco use disorder) within the past 12 months * Is currently engaging in other treatment for Alcohol Use Disorder or making intentional efforts to quit alcohol use * Is currently participating in another clinical study in which the subject is or will be exposed to an investigational or a non-investigational drug or device * Is breast-feeding, pregnant, or not using a reliable form of birth control * Reports active suicidal or homicidal ideation * Any disorder, unwillingness or inability, not covered by any of the other exclusion criteria which, in the investigator's opinion, might have jeopardized the participant's safety or compliance with the protocol

Study sites by state

Connecticut

  • Yale School of Medicine — New Haven · Recruiting now

View the official record on ClinicalTrials.gov →

Verify before you act. Medical disclaimer: content on this site is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs; always consult a licensed healthcare provider about eligibility, risks, and benefits. Trial details and enrollment status change frequently — always verify on the official registry and talk to your own clinician before contacting a study site. This page was generated from registry data and is not affiliated with the study sponsor.

Follow this trial

Get an email when our monthly digest covers enrollment changes and results for trials like this one.

Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in .env to activate this form.)

Keep researching on StudyBackedHealth